Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS: In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding. RESULTS: A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior to warfarin with respect to the primary efficacy outcome, which occurred in 130 patients in the edoxaban group (3.2%) and 146 patients in the warfarin group (3.5%) (hazard ratio, 0.89; 95% confidence interval [CI], 0.70 to 1.13; P<0.001 for noninferiority). The safety outcome occurred in 349 patients (8.5%) in the edoxaban group and 423 patients (10.3%) in the warfarin group (hazard ratio, 0.81; 95% CI, 0.71 to 0.94; P=0.004 for superiority). The rates of other adverse events were similar in the two groups. A total of 938 patients with pulmonary embolism had right ventricular dysfunction, as assessed by measurement of N-terminal pro-brain natriuretic peptide levels; the rate of recurrent venous thromboembolism in this subgroup was 3.3% in the edoxaban group and 6.2% in the warfarin group (hazard ratio, 0.52; 95% CI, 0.28 to 0.98). CONCLUSIONS: Edoxaban administered once daily after initial treatment with heparin was noninferior to high-quality standard therapy and caused significantly less bleeding in a broad spectrum of patients with venous thromboembolism, including those with severe pulmonary embolism. (Funded by Daiichi-Sankyo; Hokusai-VTE ClinicalTrials.gov number, NCT00986154.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Self-citationDabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Cited by
Items 801–900 of 1,001
Jugrin, A. V., Ustyugova, A., Urbich, M., Sunderland, T., & Lamotte, M. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1027 · Cited by 11
Drug therapy in anticoagulation: which drug for which patient?
Millar, C. M., & Laffan, M. A. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-233 · Cited by 11
Nishimoto, Y., Yamashita, Y., Morimoto, T., Chatani, R., Kaneda, K., Ikeda, N., Kobayashi, Y., Ikeda, S., Kim, K., Inoko, M., et al. (2024) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2024.04.012 · Cited by 11
Kaneda, K., Yamashita, Y., Morimoto, T., Chatani, R., Nishimoto, Y., Ikeda, N., Kobayashi, Y., Ikeda, S., Kim, K., Inoko, M., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.034412 · Cited by 11
Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid
Bejjani, A., & Bikdeli, B. (2024) · Thrombosis and Haemostasis · doi:10.1055/a-2451-4014 · Cited by 18
Galanis, T., Keiffer, G., & Merli, G. J. (2014) · Current Therapeutic Research · doi:10.1016/j.curtheres.2014.06.002 · Cited by 12
“The Hokusai-VTE trail was a randomized, double-blind, noninferiority study comparing the effects of edoxaban 60 mg once daily (or 30 mg once daily in patients with a creatinine clearance 30-50 mL/min or a body weight o60 kg) with warfarin in patients with an acute VTE.(11) The principal efficacy outcome was the incide…”
MethodInfluentialAscertainment and validation of major bleeding events in a primary care database
Ruigómez, A., Brobert, G., Suzart‐Woischnik, K., & Rodríguez, L. A. G. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4580 · Cited by 11
Direct Oral Anticoagulants in Cancer Patients
Suryanarayan, D., Lee, A. Y. Y., & Wu, C. S. T. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1693479 · Cited by 11
Chu, G. K. T., Valerio, L., van der Wall, S. J., Barco, S., Konstantinides, S., Huisman, M. V., & Klok, F. A. (2020) · Heart · doi:10.1136/heartjnl-2019-316305 · Cited by 15
Tan, S. L., Yong, Z. Y., Liew, J. E. S., Zainal, H., & Siddiqui, S. (2021) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-021-00377-w · Cited by 12
Contemporary clinical management of acute pulmonary embolism: the COPE study
Becattini, C., Agnelli, G., Maggioni, A. P., Dentali, F., Fabbri, A., Enea, I., Pomero, F., Ruggieri, M. P., Lenarda, A. D., & Gulizia, M. M. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02855-0 · Cited by 13
“These agents have been developed for clinical use according to 2 different regimens for the treatment of venous thromboembolism (6,16-21).”
MethodBistervels, I. M., Bavalia, R., Beyer‐Westendorf, J., ten Cate‐Hoek, A. J., Schellong, S., Kovacs, M. J., Falvo, N., Meijer, K., Stéphan, D., Boersma, W. G., et al. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12748 · Cited by 11
Nazarian, Z., & Arab, S. S. (2022) · Process Biochemistry · doi:10.1016/j.procbio.2022.07.025 · Cited by 11
Hurwitz, A., Massone, R., & Lopez, B. L. (2014) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2014.04.010 · Cited by 11
Beyer‐Westendorf, J., Cohen, A. T., & Monréal, M. (2015) · European Heart Journal Supplements · doi:10.1093/eurheartj/suv034 · Cited by 13
The use of anticoagulants in morbidly obese patients
Domienik‐Karłowicz, J., & Pruszczyk, P. (2015) · Cardiology Journal · doi:10.5603/cj.a2015.0054 · Cited by 11
Caterina, R. D., Ageno, W., Boriani, G., Colonna, P., Ghirarduzzi, A., Patti, G., Rossini, R., Rubboli, A., Schinco, P., & Agnelli, G. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0488-9 · Cited by 12
“In the Hokusai-VTE study [13], edoxaban was evaluated for the treatment of VTE patients.”
BackgroundMethodInfluentialClinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients
Kraaijpoel, N., van Es, N., Bleker, S. M., Brekelmans, M. P. A., Eerenberg, E. S., Middeldorp, S., Cohen, A. T., Raskob, G. E., & Buller, H. R. (2018) · Thrombosis and Haemostasis · doi:10.1160/th17-04-0274 · Cited by 11
Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT‐AF/VTE)—Trial design
Colonna, P., von Heymann, C., Santamaría, A., Matsushita, Y., & Unverdorben, M. (2018) · Clinical Cardiology · doi:10.1002/clc.23037 · Cited by 11
“Among NOAC, edoxaban—a direct factor Xa inhibitor— demonstrated noninferior efficacy to warfarin for stroke prevention in NVAF and for VTE treatment/secondary prevention and was associated with significantly reduced major or clinically relevant nonmajor (CRNM) bleeding rates.(11,12) Currently, periprocedural managemen…”
BackgroundMethodBarco, S., Granziera, S., Coppens, M., Douxfils, J., Nijkeuter, M., Riva, N., Vanassche, T., Zhang, G., Lin, M., Kamphuisen, P. W., et al. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1678546 · Cited by 11
Wu, X., Yang, S., Yu, H., Ye, L., Su, B., & Shao, Z.-H. (2019) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2019.1597620 · Cited by 11
“As compared to Warfarin, the first-line anticoagulant for the prevention of stroke and systemic thrombosis in patients with atrial fibrillation [3], the therapeutic effect of edoxaban is comparable, but the incidence of total bleeding events and cardiovascular deaths is lower, which grants it great prospects for futur…”
Yagi, S., Kagawa, K., Fujimoto, E., & Sata, M. (2019) · The Journal of Medical Investigation · doi:10.2152/jmi.66.182 · Cited by 12
Treatment of Cancer-Associated Thrombosis: Beyond HOKUSAI
Mahé, I., Elalamy, I., Gerotziafas, G., & Girard, P. (2019) · TH Open · doi:10.1055/s-0039-1696659 · Cited by 11
Nourse, J. P., & Danckwardt, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107676 · Cited by 11
Direct Oral Anticoagulant Use in Special Populations: Elderly, Obesity, and Renal Failure
White, E. M., & Coons, J. C. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01456-9 · Cited by 11
Effects of Short-Term Air Pollution Exposure on Venous Thromboembolism: A Case-Crossover Study
Johnson, S. A., Mendoza, D. L., Zhang, Y., & Pirozzi, C. S. (2021) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202010-1337oc · Cited by 11
Palareti, G., Bignamini, A. A., Cini, M., Li, Y.-J., Urbanek, T., Maďarič, J., Bouslama, K., Юрьевич, С. Г., Andreozzi, G. M., Matuška, J., et al. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02765-1 · Cited by 11
Lin, Y., Kuan, F., Chao, T., Michael Shengtao, W. U., Chen, S., Chen, M., Chung, C.-M., Chu, P., Lip, G. Y. H., & Wu, V. C. (2021) · Cancer Medicine · doi:10.1002/cam4.4241 · Cited by 11
Singh, B. B., Pai, P., Kumar, H., George, S., Mahapatra, S., Garg, V., Gupta, G. N., Makineni, K., Ganeshwala, G., Narkhede, P., et al. (2022) · Cardiology and Therapy · doi:10.1007/s40119-022-00254-w · Cited by 11
Lee, Y. J. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s72268 · Cited by 12
“31 There was a notable distinction between the intervention approaches with the NOACs among trials; dabigatran and edoxaban trials required an initial use of a parenteral anticoagulant (either heparin or LMWH), whereas rivaroxaban and apixaban were used as monotherapy without the use of a…”
Treatment Options in Massive and Submassive Pulmonary Embolism
Wadhera, R. K., & Piazza, G. (2015) · Cardiology in Review · doi:10.1097/crd.0000000000000084 · Cited by 11
“In patients with submassive PE, edoxaban has been shown to halve the risk of recurrent PE compared with warfarin.(26) Dabigatran and edoxaban are administered in fixed doses after at least 5 days of parenteral anticoagulation with UFH, LMWHs, fondaparinux, or a direct thrombin inhibitor.”
BackgroundThrombosis in an Internal Jugular Vein and an Upper Limb Deep Vein Treated with Edoxaban
Mizuho, T., Hayashi, A., Nishiyama, N., Nakamura, H., Chida, R., Komatsu, T., Nakahara, S., Kobayashi, S., & Taguchi, I. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7405 · Cited by 11
“The Hokusai-venous thromboembolism (VTE) study, which included patients with cancer, demonstrated that edoxaban was non-inferior to high-quality standard therapy and was associated with significantly less bleeding in a broad spectrum of patients (10).”
MethodKlok, F. A., Ageno, W., Barco, S., Binder, H., Brenner, B., Duerschmied, D., Empen, K., Faggiano, P. M., Ficker, J. H., Galiè, N., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-06-0434 · Cited by 12
Yami, M. S. A., McBride, A., Katragadda, C., Martin, J. R., Badreldin, H. A., Mohammed, A., Elmubark, A., Alzahrani, M., Alsheri, A., & Abraham, I. L. (2018) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-018-1777-0 · Cited by 11
Korayem, G. B., Alshaya, O. A., Alnajjar, N., Alawad, A., Alotaibi, R., Sheraim, N. B., Hakami, F. M., Alsudyyes, O. S., Alsoghayer, R. H., Alhushan, L. M., et al. (2023) · International Journal of General Medicine · doi:10.2147/ijgm.s392505 · Cited by 10
“The Hokusai-VTE and RE-COVER trials elected to start with lead-in parenteral anticoagulation for 5–10 days before starting dabigatran and edoxaban.(4,6) In contrast, the AMPLIFY, EINSTEIN-PE, and EINSTEIN-DVT trials immediately started patients on high doses of rivaroxaban (15 mg twice daily for 21 days) or apixaban (…”
MethodYoon, D., Jeong, H. E., Park, S., You, S. C., Bang, S., & Shin, J. (2023) · BMC Medicine · doi:10.1186/s12916-023-03069-1 · Cited by 11
“Warfarin for 6-month Treatment for Acute Symptomatic Venous Thromboembolism) [7], EINSTEIN-DVT (Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis) [9], EINSTEIN-PE (Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism) [10],…”
BackgroundResultCohen, O., Kenet, G., Levy‐Mendelovich, S., Tzoran, I., Brenner, B., de Ancos, C., López-Miguel, P., Varona, J. F., Catella, J., Monréal, M., et al. (2024) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-024-02957-4 · Cited by 11
“Importantly, patients with IT accounted for 2–18% of the participants included in the clinical trials that evaluated the efficacy and safety of DOACs for the treatment of VTE [10–14].”
Anticoagulation in the Management of Acute Pulmonary Embolism—A Review
del Toro-Mijares, R., Murguía, A. R., Porres‐Aguilar, M., & Mukherjee, D. (2024) · International Journal of Angiology · doi:10.1055/s-0044-1782537 · Cited by 4
y, P. A., Bayés‐Genís, A., de Isla, L. P., Sanchís, J. M., & Heras, M. (2013) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.09.004 · Cited by 10
Direct Oral Anticoagulants in the Treatment of Venous Thromboembolic Disease
Febres, L. M. S., & Manteca, J. C. (2017) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2017.01.010 · Cited by 11
Goshgarian, C., & Gorelick, P. B. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0782-6 · Cited by 10
George, C., Rahman, M., & Monagle, P. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00403-5 · Cited by 10
“Another factor Xa inhibitor currently being studied in children is edoxaban, which has been shown to be noninferior to warfarin therapy in adults with VTE [86].”
BackgroundGarcía-Escobar, I., Brozos-Vázquez, E., Abad, D. G., Martínez-Marín, V., Pachón, V., & Martín, A. J. M. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02506-4 · Cited by 13
Direct Oral Anticoagulants: A Review for the Non-Specialist
Gunawardena, T. (2021) · Hematology Reports · doi:10.4081/hr.2021.9239 · Cited by 10
Cho, M. S., Kang, D., Oh, Y., Lee, C. H., Choi, E., Lee, J. H., Kwon, C. H., Park, G., Park, H. W., Park, K., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.01.014 · Cited by 13
Yamashita, Y., Morimoto, T., Kadota, K., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., et al. (2022) · Thrombosis Research · doi:10.1016/j.thromres.2022.09.002 · Cited by 10
Gastrointestinal Bleeding on Oral Anticoagulation: What is Currently Known
Ingason, A. B., Hreinsson, J. P., & Bjornsson, E. S. (2022) · Drug Safety · doi:10.1007/s40264-022-01243-7 · Cited by 13
Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
Said, K. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2013.50 · Cited by 12
“Hokusai-VTE study was a randomized, double-blind, non-inferiority study that was conducted to evaluate efficacy and safety of edoxaban for the treatment of VTE compared with warfarin.(13) The study is named after the famous Japanese artist and painter Katsushika Hokusai.”
MethodRe-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed
Milling, T. J., & Spyropoulos, A. C. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.006 · Cited by 10
Nakashima, N., Sueta, D., Kanemaru, Y., Takashio, S., Yamamoto, E., Hanatani, S., Kanazawa, H., Izumiya, Y., Kojima, S., Kaikita, K., et al. (2017) · Thrombosis Journal · doi:10.1186/s12959-017-0128-2 · Cited by 10
“Conclusion A use of single-dose DOAC is well known to be a treatment for VTE [23].”
BackgroundDirect Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
Nakamura, M., Yamada, N., & Ito, M. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17005 · Cited by 13
Medina, A., Raskob, G. E., Ageno, W., Cohen, A. T., Brekelmans, M. P. A., Chen, C. Y.-H., GROSSO, M. A., Mercuri, M. F., Segers, A. E. M., Verhamme, P. B., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-05-0523 · Cited by 11
Godin, R., Roy, G., & Douketis, J. D. (2018) · Thrombosis Research · doi:10.1016/j.thromres.2018.03.004 · Cited by 11
State of play and future direction with NOACs: An expert consensus
Cohen, A. T., Lip, G. Y. H., Caterina, R. D., Heidbüchel, H., Zamorano, J. L., Agnelli, G., Verheugt, F. W. A., & Camm, A. J. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2018.04.001 · Cited by 11
Lamsam, L. A., Sussman, E. S., Iyer, A., Bhambhvani, H. P., Han, S. S., Skirboll, S. L., & Ratliff, J. K. (2018) · Stroke · doi:10.1161/strokeaha.118.022156 · Cited by 10
Quéré, I., Élias, A., Maufus, M., Elias, M., Sevestre, M., Galanaud, J. ‐., Bosson, J., Bura-Rivière, A., Jurus, C., Lacroix, P., et al. (2019) · JMV-Journal de Médecine Vasculaire · doi:10.1016/j.jdmv.2018.12.003 · Cited by 14
Komiyama, S., Nagashima, M., Taniguchi, T., Rikitake, T., & Morita, M. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00757-w · Cited by 10
Nakamura, M., Yamada, N., Asamura, T., Shiosakai, K., & Uchino, K. (2019) · Circulation Journal · doi:10.1253/circj.cj-18-1362 · Cited by 11
Balbi, G. G. M., Pacheco, M. D. S., Monticielo, O. A., Funke, A., Danowski, A., Santiago, M. B., Staub, H. L., Rêgo, J., & ANDRADE, D. C. O. D. (2020) · Revista Brasileira de Reumatologia · doi:10.1186/s42358-020-00125-9 · Cited by 15
Organisation of care for patients using direct oral anticoagulants
Gulpen, A. J. W., van Dijk, J. K., Damen, N. L., Cate, H. T., Schalla, S. M., & ten Cate‐Hoek, A. J. (2020) · Netherlands Heart Journal · doi:10.1007/s12471-020-01436-8 · Cited by 10
Saito, K., Ishii, K., Furuta, K., Kobayashi, M., Wada, Y., & Morishita, E. (2020) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2020.105320 · Cited by 10
Outpatient treatment of emergency department patients diagnosed with venous thromboembolism
Stubblefield, W. B., & Kline, J. A. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.1916299 · Cited by 10
Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy
Nitta, K., Imamura, H., Yashio, A., Kashima, S., & Mochizuki, K. (2016) · Case Reports in Critical Care · doi:10.1155/2016/7938062 · Cited by 10
Direct Oral Anticoagulants: Novel Approach for the Treatment of Thrombosis in Pediatric Patients?
Mikler, J., Samoš, M., Bolek, T., Škorňová, I., Stančiaková, L., Staško, J., & Mokáň, M. (2019) · Pediatric Cardiology · doi:10.1007/s00246-019-02159-3 · Cited by 10
Influence of glycyrrhetinic acid on the pharmacokinetics of warfarin in rats
Song, J., Dai, H., Zhang, H., Liu, Y., & Zhang, W. (2019) · Xenobiotica · doi:10.1080/00498254.2019.1671637 · Cited by 10
“Warfarin is the most commonly prescribed anticoagulant in the world (Eriksson & Wadelius, 2012) and is used for the prevention of venous thromboembolism (Hokusai et al., 2013), for the treatment of atrial fibrillation and deep vein thrombosis (Mueller et al., 2017; Weir et al., 2018).”
BackgroundMcIlroy, G., Smith, N., Lokare, A., Beale, K., & Kartsios, C. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02042-6 · Cited by 12
Beyer‐Westendorf, J., Marten, S., Naue, C., Tittl, L., Hänsel, U., Beyer-Westendorf, I., Mizera, H., Schreier, T., Festerling, E., Reitter, A., et al. (2020) · Thrombosis Research · doi:10.1016/j.thromres.2020.03.021 · Cited by 11
Parakh, R., Krishna, P. R., Amin, P. R., Bedi, V., Desai, S., Dumra, H. S., Gupta, P., Gupta, V. G., Hydrabadi, R., Kamerkar, D. R., et al. (2016) · PubMed · Cited by 10
Ohmori, H., Kanaoka, Y., Yamasaki, M., Takesue, H., & Sumimoto, R. (2018) · Annals of Vascular Diseases · doi:10.3400/avd.oa.18-00028 · Cited by 10
Minno, M. N. D. D., Ageno, W., & Dentali, F. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12746 · Cited by 10
The advent of the novel oral anticoagulants
Prandoni, P. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.210 · Cited by 9
Direct Oral Anticoagulants for the Prevention and Acute Treatment of Cancer-Associated Thrombosis
Attard, L. M., Gatt, A., Bertoletti, L., Delluc, A., & Riva, N. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s271411 · Cited by 10
Yin, Q., Zheng, X., Ni, X., Wang, Y., Huang, X., Song, Y., Han, L., Huang, Y., & Bian, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1615284 · Cited by 10
The new oral anticoagulants: clinical use and reversal agent development
Costin, J. C., Ansell, J., Bakhru, S., Laulicht, B., & Steiner, S. S. (2015) · ISBT Science Series · doi:10.1111/voxs.12160 · Cited by 9
Masotti, L., Vannucchi, V., Poggi, M., & Landini, G. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000356 · Cited by 10
The Role of New Oral Anticoagulants (NOACs) in Cancer Patients
Ravikumar, R., Lim, C. S., & Davies, A. H. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_112 · Cited by 10
Younis, M., Elkaryoni, A., Williams, G. W., Jakhar, I., Suman, S., Simon, S., & Salzman, G. A. (2020) · Cureus · doi:10.7759/cureus.10006 · Cited by 9
Kitano, T., Nabeshima, Y., Kataoka, M., & Takeuchi, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255280 · Cited by 9
Ingason, A. B., Rumba, E., Hreinsson, J. P., Agustsson, A. S., Lund, S. H., Pálsson, D. A., Reynisson, I. E., Guðmundsdóttir, B. R., Onundarson, P. T., Tryggvason, G., et al. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13498 · Cited by 10
Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients
Mansell, H., SHOKER, A. S., Alcorn, J., Fenton, M. E., Tam, J. S., Semchuk, W., Bashir, B., Kraft, W. K., Yao, S., & Douketis, J. D. (2022) · Clinical and Translational Science · doi:10.1111/cts.13284 · Cited by 9
Ono, R., Nishimura, K., Takahashi, H., Hori, Y., Fukushima, K., & Kobayashi, Y. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02312-5 · Cited by 9
“Factor Xa (FXa) inhibitors, including apixaban, edoxaban, and rivaroxaban, have been used for treating venous thromboembolism (VTE) and preventing stroke and systemic embolism for people with non-valvular atrial fibrillation (NVAF) (Giugliano et al. 2013; Granger et al. 2011; Patel et al. 2011; Agnelli et al. 2013; Ho…”
BackgroundYamashita, Y., Morimoto, T., Kadota, K., Takase, T., Hiramori, S., Kim, K., Oi, M., Akao, M., Kobayashi, Y., Toyofuku, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-26947-9 · Cited by 9
Park, D. Y., An, S., Arif, A. W., Sana, M. K., & Vij, A. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03067-4 · Cited by 9
Lafaie, L., Poénou, G., Hanon, O., López‐Jiménez, L., Nieto, J. A., Lorenzo, A., Porras, J. A., Lumbierres, M., Bertoletti, L., Monréal, M., et al. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18626 · Cited by 12
Self-citationYamashita, Y., Fukasawa, T., Takeda, C., Takeuchi, M., Ono, K., & Kawakami, K. (2023) · Circulation Journal · doi:10.1253/circj.cj-23-0818 · Cited by 11
New Triazole-Based Potent Inhibitors of Human Factor XIIa as Anticoagulants
Woodland, M. D., Thompson, A. A., Lipford, A., Goyal, N., Schexnaildre, J. C., Mottamal, M., Afosah, D. K., & Al‐Horani, R. A. (2024) · ACS Omega · doi:10.1021/acsomega.3c09335 · Cited by 12
Update in venous thromboembolism pathophysiology, diagnosis, and treatment for surgical patients
Coleman, D. M., Andrea, T., & Henke, P. K. (2015) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2015.04.003 · Cited by 9
Mahan, C. E. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1164-4 · Cited by 10
“Edoxaban dosage is 60 mg daily after at least 5 days of parenteral lead in and reduced to 30 mg daily if creatinine clearance (CrCl) is 30–50 mL/ min or body weight \60 kg [15].”
BackgroundChanging paradigms in the management of deep vein thrombosis
Lang, K. J., Saha, P., Roberts, L. N., & Arya, R. (2015) · British Journal of Haematology · doi:10.1111/bjh.13431 · Cited by 9
Bleeding Risk and Mortality of Edoxaban: A Pooled Meta-Analysis of Randomized Controlled Trials
Li, S., Liu, B., Xu, D., & Xu, Y. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095354 · Cited by 9
“Patients were predominantly men and received treatment for nonvalvular atrial fibrillation (NVAF, n = 23,022[9,11,12,13]), deep vein thrombosis (DVT, n = 4,921[10]), or pulmonary embolism (PE, n = 3,319[10]).”
BackgroundResultInfluentialPatient satisfaction with extended-interval warfarin monitoring
Carris, N. W., Hwang, A. Y., Smith, S. M., Taylor, J. R., Sando, K. R., Powell, J., Rosenberg, E. I., Zumberg, M. S., Gums, J. G., Dietrich, E. A., et al. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1385-9 · Cited by 10
Acanfora, D., Acanfora, C., Scicchitano, P., Longobardi, M., Furgi, G., Casucci, G., Lanzillo, B., Dentamaro, I., Zito, A., Incalzi, R. A., et al. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0436-5 · Cited by 11
Wang, X., Ma, M., Reddy, A. G. K., & Hu, W. (2017) · Tetrahedron · doi:10.1016/j.tet.2017.01.021 · Cited by 9
Renal Function and Direct Oral Anticoagulant Treatment for Venous Thromboembolism
Fanikos, J. R., Burnett, A., Mahan, C. E., & Dobesh, P. P. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.06.004 · Cited by 9
Jaffer, I., & Weitz, J. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00149-9 · Cited by 9
Bolek, T., Samoš, M., Škorňová, I., Kovář, F., Galajda, P., Staško, J., Kubisz, P., & Mokáň, M. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000593 · Cited by 9
Cohen, A. T., Hoffmann, U., Hainaut, P., Gaine, S., Ay, C., Coppens, M., Schindewolf, M., Jiménez, D., Brüggenjürgen, B., Lévy, P., et al. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.08.014 · Cited by 9
Highsmith, E. A., Morton, C., Varnado, S., Donahue, K. R., Sulhan, S., & Lista, A. D. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1779 · Cited by 9
“5 (14-15) on admission, and the median hematoma volume was 14.”
BackgroundIbrahim, E., Norris, L., & Saadeh, F. A. (2021) · Thrombosis Update · doi:10.1016/j.tru.2021.100038 · Cited by 11
Hamedani, N. S., Biswas, A., Rudan, O., Tönges, R., Meyring, C., Tölle, F., Mayer, G., Oldenburg, J., Müller, J., & Pötzsch, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040677 · Cited by 9
Metadata
- Authors
- The Hokusai-VTE Investigators
- Corresponding author
- The Hokusai-VTE Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-10-10
- Volume
- 369
- Issue
- 15
- Pages
- 1406-1415
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2160625453
- Cited by
- 1,869
- References
- 25
- Citations by year
- 2026: 52 · 2025: 75 · 2024: 112 · 2023: 104 · 2022: 116 · 2021: 128 · 2020: 179 · 2019: 170 · 2018: 190 · 2017: 173 · 2016: 210 · 2015: 173 · 2014: 161 · 2013: 25
- FWCI
- 165.78
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Institutional Research Information System (Università degli Studi di Trento) (submittedVersion)
- Iris (University of Trento) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- Daiichi-Sankyo
- LEO Pharma
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- warfarin, venous thromboembolism, factor Xa inhibitors, deep vein thrombosis, pulmonary embolism, recurrent venous thromboembolism, non-inferiority, bleeding risk, right ventricular dysfunction, N-terminal pro-brain natriuretic peptide, anticoagulation, heparin, renal dysfunction, body weight
- MeSH terms
- Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Pulmonary Embolism, Warfarin, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.